openPR Logo
Press release

Focal Segmental Glomerulosclerosis (FSGS) Market: to expand at a healthy CAGR from 2017 to 2025

06-19-2018 05:14 PM CET | Health & Medicine

Press release from: Transparency Market Research

Focal Segmental Glomerulosclerosis (FSGS) Market: to expand

Focal segmental glomerulosclerosis Market: Snapshot

Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on rare diseases too are proving beneficial for the market for focal segmental glomerulosclerosis.

Rising at a 8.0% CAGR from 2017 to 2025, the global focal segmental glomerulosclerosis (FSGS) market will likely become worth US$15.83 bn by 2025-end fromUS$7.82 bn in 2016, finds a report by Transparency Market Research.

Get PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31505

Primary Focal Segmental Glomerulosclerosis Garners Greater Market Share due to Awareness About it

Depending upon the disease type, the market can be bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Of the two, the segment of primary focal segmental glomerulosclerosis held a mammoth 79.8% share in the market in 2016. Also known as primary idiopathic/genetic focal segmental glomerulosclerosis, primary focal segmental glomerulosclerosis is a kind of the focal segmental glomerulosclerosis disease without a known or obvious cause. Growing awareness about the disease and its management is at the forefront of driving growth in the segment.

Depending upon the management of the disease, the global market for focal segmental glomerulosclerosis (FSGS) can again be split broadly into diagnosis and treatment. The segment of diagnosis can be further divided into creatine test, kidney biopsy, etc. The segment of treatment again can be further divided into drug therapy, kidney transplant, and dialysis. At present, the treatment segment contributes to most of the revenue in the market for focal segmental glomerulosclerosis (FSGS). This is because of the massive unmet requirements in the market. A promising pipeline of novel molecules and their approval will continue boosting the segment in the next couple of years.

Get Sample Copy of The Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31505

Considerable Penetration of Treatment Drives U.S. Market to Fore

Geographically, North America accounts for a leading share in the market for focal segmental glomerulosclerosis because of the presence of a properly structured health care industry and availability of reimbursement policies with wider coverage. The U.S. is mainly serving to drive the market in North America due to the greater uptake of advanced and high-cost drug therapies, considerable penetration of treatment, and helpful reimbursement policies. Another factor stoking market growth in the U.S. is the classification of focal segmental glomerulosclerosis (FSGS) drugs under orphan disease drugs categories – companies involved in the production and clinical trials of drugs for orphan diseases receive exemption from payment of new drug application fee, provision of tax credits on clinical research, waivers for post-approval annual establishment and product fees, and exclusive marketing rights up to a period of seven years.

Europe trails North America in terms of market share. In 2016, the segment accounted for a share of 25.5%. Vis-à-vis growth rate, Asia Pacific is expected to outshine all other regions. The market in the region is being powered primarily by China which in turn is being propelled by the increasing diagnosis rate of focal segmental glomerulosclerosis, stupendous growth in the healthcare industry, and availability of drugs and dialysis at a lower price.

Some of the key participants in the global market for focal segmental glomerulosclerosis (FSGS) are Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

Get Discount –

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=31505

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Focal Segmental Glomerulosclerosis (FSGS) Market: to expand at a healthy CAGR from 2017 to 2025 here

News-ID: 1089165 • Views: 346

More Releases from Transparency Market Research

Osteoporosis Drugs Market Companies Analysis, Advancement and Precise Outlook …
Transparency Market Research (TMR) has published a new report titled, ‘Osteoporosis Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global Osteoporosis Drugs market was valued at US$ 11.5 Bn in 2018 and is projected to contract at a CAGR of 0.3% from 2019 to 2027. Overview Osteoporosis is a chronic and life-threatening disease, in which microstructure of bones is altered due to
Remote Patient Monitoring Devices Market News Research Report 2020
The global remote patient monitoring devices market is foreseen in a report by Transparency Market Research (TMR) to show a decently consolidated nature coupled with intense competition between key players. Recently, a larger aggregate share was held by a few prominent names of the market. F. Hoffmann-La Roche Ltd., AMD Global Telemedicine, and Honeywell HomMed LLC are some of the leading companies operating in the market. Merger and acquisition could
Oxygen Therapy Devices Market is Thriving Worldwide By Size, Revenue, Emerging T …
The demand within the global oxygen therapy devices market is projected to increase as improved medical procedures make their way into the healthcare industry. Towards the end of last year, a group of high-school students became victims of gas poisoning across a large building in Suwon. The absence of proper medical equipment for oxygen therapy became a matter of regional outrage. In this review, Transparency Market Research (TMR) looks into
Covid-19 Impact on Organic Turmeric Market: Present Scenario and Future Growth P …
The report details an exhaustive account of the global organic turmeric market along with numerous associated factors. Some of these factors that are included in the report are drivers, restraints, competitive analysis, latest trends and opportunities, geographical outlook, and many other aspects. The study covered in the report spans a forecast period from 2018 to 2026. From an overall perspective, the report is expected to exist as a valuable insight

All 5 Releases


More Releases for FSGS

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population. Download the sample report @ https://www.pharmaproff.com/request-sample/1090 FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two
Focal Segmental Glomerulosclerosis (FSGS) Market: Launch of Pipeline Products in …
Focal segmental glomerulosclerosis Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients worldwide and about 14,000 to 16,000 new cases are diagnosed annually. The rising numbers along the considerable untapped opportunities in the market on account of a limited number of pipeline products are serving to boost it. Continued thrust by non-government organizations to increase awareness about the rare disease and increasing allocation towards research on
Global Focal Segmental Glomerulosclerosis (FSGS) Market to Grow at 8% CAGR throu …
A new comprehensive study titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” has recently been added to the vast database of Market Research Reports Search Engine (MRRSE). The global focal segmental glomerulosclerosis (FSGS) market is likely to grow at a CAGR of 8% during the assessment period, and surpass US$ 15 Bn in terms of revenues. Download Sample Copy in a PDF
Global Focal Segmental Glomerulosclerosis (FSGS) Market: Industry Development Sc …
Market Research Report Search Engine (MRRSE) recently announced the addition of a new research study to its comprehensive collection of research reports. The research report, titled “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” offers a detailed analysis of the market providing insights into the market dynamics that are expected to influence the overall market positively in the next few years. Furthermore,
Focal Segmental Glomerulosclerosis (FSGS) Market: Comprehensive Analysis and Fut …
A latest research report titled as “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025”. has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the present state and future prospect for the global market. It provides valuable information to the industry insiders, potential entrants or
Global Focal Segmental Glomerulosclerosis (FSGS) Market Anticipated to Surge at …
New research report offers a comprehensive analysis of the “Focal Segmental Glomerulosclerosis (FSGS) Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025” The main objective of this report is to deliver insightful information and clear-cut facts pertaining to the growth trajectories of the market. Request to view Sample Report @ https://www.mrrse.com/sample/4351 Global Focal segmental glomerulosclerosis (FSGS) Market: Snapshot Focal segmental glomerulosclerosis (FSGS), a rare health condition, afflicts around 210,200 patients